CASTLEFORD, England, June 22, 2012 /PRNewswire/ --
We are pleased to announce the launch of Rivastigmine capsules for generic prescription.
Rivastigmine is a version of Exelon® (Rivastigmine) from Novartis. It is indicated in the symptomatic treatment of mild to moderately severe Alzheimer's dementia. And in the symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Rivastigmine capsules are available immediately in Teva 360 livery, as follows:
Rivastigmine Pack size x 28
Strength 1.5mg 3mg 4.5mg 6mg
Brand Price GBP33.25 GBP33.25 GBP33.25 GBP33.25
Initial Teva Retail Price GBP18.29 GBP18.29 GBP18.29 GBP18.29
Rivastigmine Pack size x 56
Strength 1.5mg 3mg 4.5mg 6mg
Brand Price GBP66.51 GBP66.51 GBP66.51 GBP66.51
Initial Teva Retail Price GBP36.58 GBP36.58 GBP36.58 GBP36.58
Alzheimer's UK estimates the financial cost of dementia to the UK will be over £23 billion in 2012[1].
Kim Innes, Commercial Director at Teva said: "We're really pleased to be making more medicines accessible for more people with the launch of Rivastigmine capsules. So far this year, we've launched 20 new products, including ten day-one patent expiries, which is good for Pharmacy because new products provide opportunities for increasing margins and keeping costs down. But, more importantly it also means we continue to help save the NHS over £9bn a year."
New or existing customers can order through a Teva Territory Sales Manager, their wholesaler, or call 0800 085 8621
For more information, visit http://www.tevauk.com.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.
1. Checked on 14 June 2012 - http://alzheimers.org.uk/site/scripts/documents_info.php?documentID=341
For media enquiries, contact the Teva UK media team on +44(0)1977-628500, or email media.enquiries@tevauk.com.
Share this article